Levodopa did not show a reduction in depression after stroke
A planned analysis found similar depression rates with levodopa/carbidopa and placebo, with uncertainty that still allows benefit or harm.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
This analysis did not find evidence that levodopa/carbidopa reduced depression after stroke compared with placebo. Participants had no previous depression and had taken most of their assigned medication. The confidence interval allows both lower and higher odds of depression, so the result should not be read as proof that the treatments are equivalent.
Eligibility required medication adherence and an available depression assessment. People with previous depression were excluded, limiting the population this result describes.
What researchers found
Odds of questionnaire-defined post-stroke depression
Levodopa versus placebo at 3 months; the difference was not statistically significant.
What counted as depression
Depression was defined by reaching a prespecified threshold on a patient-reported questionnaire. This endpoint describes depression status at follow-up; the abstract does not report a clinical diagnostic interview or changes in symptom severity.
What the comparison showed
Depression frequencies were similar between groups. The odds ratio summarizes their relative odds, rather than a percentage reduction in depression, and its confidence interval spans results favoring either levodopa or placebo.
The original publication
The impact of levodopa on post-stroke depression: the ESTREL-depression-study.
Sauter MI, Kaufmann JE, Boos L et al.
Eur Stroke J · 2026
- PubMed ID
- 41701756
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.